Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.
Publication|Articles|July 20, 2026
Supplements and Featured Publications
- TONMYA® (cyclobenzaprine HCl sublingual tablets): An Innovative Approach to Fibromyalgia Management
TONMYA® (cyclobenzaprine HCl sublingual tablets): An Innovative Approach to Fibromyalgia Management
Listen
0:00 / 0:00
This Clinical Brief was sponsored by Tonix Medicines, Inc.
Advertisement
This clinical brief reviews the clinical and economic impact of fibromyalgia, examines limitations of existing treatment approaches, and introduces a new treatment option.
Advertisement
Related to this article
Fibrosis stage, not MASH resolution, best predicts mortality, which should shape trial end points, says Georgetown's Zobair Younossi, MD, MPH.
Remibrutinib (Rhapsido; Novartis) is the only treatment with approved uses in both chronic spontaneous urticaria and symptomatic dermographism.
Leukemia survivors given high-risk ALL therapy had hip bone density about 90% of matched controls, without the partial normalization seen in other groups.
A legal fight over a single amino acid could set retatrutide's exclusivity window, its Medicare negotiation clock, and its competitive future.
Sacral neuromodulation is still considered the gold standard for refractory overactive bladder, with tibial nerve stimulation a less invasive option.
FDA approved tucatinib maintenance for HER2-positive metastatic breast cancer following induction therapy based on the 654-patient HER2CLIMB-05 trial.
The Omaha-based practice will hand its inbound faxes and document management to artificial intelligence (AI) agents, with outside records retrieval to follow.
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know if Retatrutide Is Classified as a Biologic
2
Predoc and Nebraska Cancer Specialists: Not Letting the Fax Be the Fumble
3
Sacral Neuromodulation Still Seen as OAB Gold Standard in Review
4
FDA Approves Tucatinib Maintenance for HER2+ Metastatic Breast Cancer
5